AC Immune News

Calendar of U.S. Earnings Expected in the Week Ahead

Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo

Dow JonesApr 25 06:00 ET

CALM,PLAY and VNDA Are Among After Hour Movers

Seeking AlphaApr 2 16:43 ET

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)

TipRanksMar 19 01:50 ET

Express News | HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target

Moomoo 24/7Mar 15 06:41 ET

AC Immune Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 380.48% HC Wainwright & Co. → $16 Reiterates Buy → Buy 11/13/2023 380.48% HC Wainwright & Co. →

BenzingaMar 15 06:40 ET

Buy Rating for AC Immune SA on Promising Alzheimer's Vaccine Trial Design and Potential Accelerated Approval

TipRanksMar 15 06:25 ET

Further Weakness as AC Immune (NASDAQ:ACIU) Drops 12% This Week, Taking Three-year Losses to 58%

Yahoo FinanceMar 15 06:19 ET

AC Immune Files $350 Million Mixed Shelf

AC Immune (ACIU) filed a registration statement Thursday for the potential sale of up to $350 million of its securities from time to time. The filing covers the sale of the company's common shares, de

MT NewswiresMar 15 03:35 ET

AC Immune Files $350M Mixed Securities Shelf

Seeking AlphaMar 14 16:55 ET

Express News | AC Immune SA Reported FY23 Revenue of CHF14.80M Vs CHF3.94M YoY, EPS Loss of CHF(0.64) Vs CHF(0.85) YoY, Cash Balance of CHF103.1M

Moomoo 24/7Mar 14 07:17 ET

AC Immune GAAP EPS of -$0.64 Beats by $0.17, Revenue of $14.8M Beats by $3.37M

Seeking AlphaMar 14 07:12 ET

AC Immune 2023 Rev CHF14.8M >ACIU

AC Immune 2023 Rev CHF14.8M >ACIU

Dow JonesMar 14 07:06 ET

Press Release: AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update -- ACI-24.060 ABATE Phase 2 t

Dow JonesMar 14 07:00 ET

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

PDF Version 447.8 KB AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2

AC ImmuneMar 14 00:00 ET

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)

TipRanksMar 11 01:00 ET

AC Immune Announces Upcoming Presentations at AD/PD 2024

PDF Version 154.8 KB AC Immune Announces Upcoming Presentations at AD/PD 2024Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024

AC ImmuneFeb 22 00:00 ET

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

Yahoo FinanceFeb 21 10:43 ET

Express News | AC Immune Received Decision To Grant European Patent EP3735411 "1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE"

Moomoo 24/7Feb 8 12:37 ET

Buy Rating Affirmed for AC Immune SA Amid Promising Immunotherapy Program Developments

TipRanksFeb 1 06:28 ET

AC Immune Focused on Immunotherapies After Termination of Genentech Licensing Deal -- Market Talk

1023 ET - AC Immune is focused on progressing its three immunotherapies targeting Alzheimer's and Parkinson's disease after the termination of its collaboration agreements with Roche's Genentech for c

WSJJan 22 10:23 ET